Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Epilepsy Behav ; 79: 162-168, 2018 02.
Article in English | MEDLINE | ID: mdl-29291547

ABSTRACT

PURPOSE: The aim of our study was to assess the management of drug intake and potential barriers to adherence reported by two different patient groups. METHODS: The study was performed in cooperation with the Regional Chamber of Pharmacists of Rhineland-Palatinate and three neurologists in private practice specialized in epileptology. In total, 108 patients surveyed in 43 pharmacies (Group P) and 118 patients treated by the specialized neurologists (Group N) completed anonymously a questionnaire on intake of antiepileptic drugs (AEDs). The statistical evaluation was performed using nonparametric tests and logistic regression analyses. RESULTS: Group N more often used adherence aids, compared with Group P (68.6% vs. 46.3%, p<0.01), and the number of doses per day was significantly lower in Group N (Mann-Whitney test, p=0.046), but the percentage of patients who reported problems with the regular intake of their medication did not differ significantly between groups (Group N vs. P: 47.0% vs. 40.0%). If patients noticed that they missed a dose, 45.3% completely skipped the missed dose (Group N vs. P: 43.0% vs. 48.1%, n.s.). In a multivariate analysis, significant risk factors of problems with regular drug intake were age<25yrs. (p<0.01) and patient-reported adverse effect of AED (p<0.01), followed by the number of AED doses per day (p<0.05), while gender, intake habits, usage of adherence aids, and patient-rated efficacy of AEDs were not significant. CONCLUSION: Patients treated by neurologists specialized in epileptology did not report less problems with adherence than patients surveyed in pharmacies. Since barriers for a regular intake are diverse, the use of a short questionnaire on management of drug intake may lead to an individually tailored counseling of patients to improve adherence.


Subject(s)
Anticonvulsants/therapeutic use , Epilepsy/drug therapy , Medication Adherence/psychology , Adolescent , Adult , Aged , Epilepsy/psychology , Female , Humans , Male , Medication Therapy Management , Middle Aged , Pharmacists , Socioeconomic Factors , Surveys and Questionnaires , Time Factors
2.
Seizure ; 26: 49-55, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25799902

ABSTRACT

PURPOSE: This study used an electronic practice management software in daily routine to gather long-term disease and cost-of-illness (COI) data in patients with epilepsy in Germany. METHODS: Data on socio-economic status, course of epilepsy as well as direct and indirect costs were recorded using practice software-based questionnaires. RESULTS: In 2011 we enrolled 359 patients (170 male (47.4%); mean age 50.5±20.7 years) in six neurological practices. The majority of patients had been in long-term seizure remission for more than one year (n=200, 55.7%) and in more than two-thirds the anti-epileptic drug (AED) monotherapy (n=248, 69.1%) was used. Levetiracetam (31%), lamotrigine (26%) and valproate (24%) were the drugs prescribed most frequently. Total annual direct costs amounted to €1698 per patient with anticonvulsants (59.9% of total direct costs) and hospitalization (30.0%) as the main cost factors. Of the patients enrolled 252 (70.2%) were of working age and indirect annual costs due to absenteeism amounted to €745 per patient. Potential cost-driving factors were seizure frequency and a recent diagnosis of epilepsy associated with higher costs. Anticonvulsant treatment in patients aged 65 years and older was associated with lower drug costs due to prescription of older AEDs. CONCLUSION: We were able to demonstrate that electronic practice management software can easily be used to perform long-term health economic evaluations with a bottom-up approach. The combination of both physician- and patient-based electronic databases will facilitate performing less expensive studies, but at the same time simplify large, prospective and multicentre clinical trials.


Subject(s)
Cost of Illness , Disease Management , Electronics/economics , Epilepsy/economics , Epilepsy/therapy , Adolescent , Adult , Aged , Aged, 80 and over , Anticonvulsants/economics , Anticonvulsants/therapeutic use , Cost-Benefit Analysis , Drug Prescriptions/economics , Drug Prescriptions/statistics & numerical data , Electronics/methods , Female , Germany , Humans , Male , Middle Aged , Software , Young Adult
3.
Epilepsia ; 54(2): 256-64, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23294455

ABSTRACT

PURPOSE: Neurexins are neuronal adhesion molecules located in the presynaptic terminal, where they interact with postsynaptic neuroligins to form a transsynaptic complex required for efficient neurotransmission in the brain. Recently, deletions and point mutations of the neurexin 1 (NRXN1) gene have been associated with a broad spectrum of neuropsychiatric disorders. This study aimed to investigate if NRXN1 deletions also increase the risk of idiopathic generalized epilepsies (IGEs). METHODS: We screened for deletions involving the NRXN1 gene in 1,569 patients with IGE and 6,201 controls using high-density oligonucleotide microarrays. KEY FINDINGS: We identified exon-disrupting deletions of NRXN1 in 5 of 1,569 patients with IGE and 2 of 6,201 control individuals (p = 0.0049; odds ratio (OR) 9.91, 95% confidence interval (CI) 1.92-51.12). A complex familial segregation pattern in the IGE families was observed, suggesting that heterozygous NRXN1 deletions are susceptibility variants. Intriguingly, we identified a second large copy number variant in three of five index patients, supporting an involvement of heterogeneous susceptibility alleles in the etiology of IGE. SIGNIFICANCE: We conclude that exon-disrupting deletions of NRXN1 represent a genetic risk factor in the genetically complex predisposition of common IGE syndromes.


Subject(s)
Cell Adhesion Molecules, Neuronal/genetics , Epilepsy, Generalized/genetics , Exons/genetics , Nerve Tissue Proteins/genetics , Adult , Age of Onset , Anticonvulsants/therapeutic use , Calcium-Binding Proteins , Case-Control Studies , DNA Copy Number Variations , Electroencephalography , Epilepsy, Generalized/drug therapy , Epilepsy, Generalized/psychology , Family , Female , Fructose/analogs & derivatives , Fructose/therapeutic use , Gene Deletion , Genotype , Humans , Infant , Lamotrigine , Male , Microarray Analysis , Middle Aged , Neural Cell Adhesion Molecules , Neuropsychological Tests , Odds Ratio , Pedigree , Topiramate , Triazines/therapeutic use , Valproic Acid/therapeutic use
4.
Doc Ophthalmol ; 104(2): 151-70, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11999623

ABSTRACT

PURPOSE: We investigated functional, morphological and electrophysiological changes in patients under anti-epileptic therapy with vigabatrin (VGB), a GABA aminotransferase inhibitor. METHODS: 20 epileptic patients treated with vigabatrin (age range 25-66 years) were enrolled in this study. The referrals were made by the treating neurologist, based on suspected or known visual field changes in these patients. Two patients had vigabatrin monotherapy, 18 patients were treated with vigabatrin in combination with other antiepileptic drugs. None of the patients reported visual complaints. Patients were examined with psychophysical tests including colour vision (Farnsworth D15), dark adaptation threshold, Goldmann visual fields and Tuebingen Automated Perimetry (90 degrees). A Ganzfeld ERG and an EOG following the ISCEV standard protocol were also obtained. Additionally, all patients were examined with the VERIS multifocal ERG including recordings of multifocal oscillatory potentials. RESULTS: Visual acuity, anterior and posterior segments, colour vision and dark adaptation thresholds were normal in all patients. Of 20 patients, 18 presented visual field constriction. All patients with visual field defects revealed altered oscillatory potentials waveforms in the ERG, especially in those patients with marked visual field defects. Multifocal oscillatory potentials were also delayed in those patients. In some patients a delayed cone single flash response (6/20), a reduced mERG amplitude (12/20) and a reduced Arden ratio (9/20) were found. CONCLUSIONS: The present data indicate an effect of vigabatrin on the inner retinal layers. Since abnormalities of the oscillatory potentials were seen in all patients with visual field defects a dysfunction of GABA-ergic retinal cell transmission might be assumed.


Subject(s)
Anticonvulsants/adverse effects , Epilepsy/drug therapy , Epilepsy/physiopathology , Retina/drug effects , Retina/physiopathology , Vigabatrin/adverse effects , Visual Fields/drug effects , Adult , Aged , Anticonvulsants/therapeutic use , Drug Therapy, Combination , Electrooculography , Electroretinography , Female , Humans , Male , Middle Aged , Vigabatrin/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...